Phathom Pharmaceuticals has been launched with $140m in debt and equity financing to commercialise a gastrointestinal disease drug licensed from Takeda.
Pharmaceutical firm Takeda and venture capital firm Frazier Healthcare Partners officially launched a US-based biopharmaceutical startup called Phathom Pharmaceuticals yesterday with $90m of crossover financing and $50m of debt financing.
Frazier led the equity portion of the round, investing with Medicxi, RA Capital Management, Abingworth, Janus Henderson Investors, BVF Partners, Greenspring Associates, Richard King Mellon Foundation, Sahsen Ventures and undisclosed private investors. Silicon Valley Bank supplied a $50m loan facility.
Phathom is developing treatments for gastrointestinal diseases and disorders such as…
